Telix Pharmaceuticals is trading at $9.53, up 5.43%, following its November 4 Capital Markets Day outlining commercial growth plans and its late-stage pipeline.
- Management reiterated FY2026 revenue guidance of $950 million to $970 million, tracking toward the upper end.
- Management described a potential path to about $1.5 billion in 2027 revenue, including ITM.
- Shares closed at $9.03 on November 3; no live volume information was provided.